Rivaroxaban is used for: Atrial fibrillation; Strokes; Deep venous thrombosis.
Recorded in the NepalDoc medicine catalog for Rivaroxaban.
XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation for treatment of deep vein thrombosis (DVT) for treatment of pulmonary embolism (PE) for reduction in the risk of recurrence of DVT or PE for the prophylaxis of DVT…
From the U.S. FDA-approved label for Rivaroxaban. Full label: DailyMed.
XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation for treatment of deep vein thrombosis (DVT) for treatment of pulmonary embolism (PE) for reduction in the risk of recurrence of DVT or PE for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.
From the U.S. FDA-approved label for Rivaroxaban. Full label: DailyMed.
Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food Treatment of DVT and/or PE: 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE: 10 mg once daily with or without food…
Directions from the U.S. FDA-approved label for Rivaroxaban — your doctor or pharmacist may advise differently.
XARELTO is contraindicated in patients with: active pathological bleeding severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) Active pathological bleeding Severe hypersensitivity reaction to XARELTO
Excerpt from the U.S. FDA-approved label for Rivaroxaban. Talk to a pharmacist or doctor before use.
Risk of bleeding: XARELTO can cause serious and fatal bleeding Pregnancy-related hemorrhage: Use XARELTO with caution in pregnant women due to the potential for obstetric hemorrhage and/or emergent delivery Prosthetic heart valves: XARELTO use not recommended Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: XARELTO use not recommended 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.
Warnings and precautions excerpt from the U.S. FDA-approved label for Rivaroxaban — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are also discussed in other sections of the labeling: Increased Risk of Stroke After Discontinuation in Nonvalvular Atrial Fibrillation Bleeding Risk Spinal/Epidural Hematoma The most common adverse reaction (>5%) in adult patients was bleeding The most common adverse reactions (>10%) in pediatric patients were bleeding, cough, vomiting, and gastroenteritis To report…
Excerpt from the U.S. FDA-approved label for Rivaroxaban — not a complete list. Talk to a pharmacist or doctor about side effects.
6 brands · 2 makers in the NepalDoc catalog — see the full Rivaroxaban guide →
Of tablets, granules and reconstituted suspension: Store at room temperature between 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). Do not freeze the granules or reconstituted suspension. Keep out of the reach of children.
Storage information from the U.S. FDA-approved label for Rivaroxaban.
What is RIVAROX?
RIVAROX 20mg Tablet is a Rivaroxaban medicine made by QbD Pharmaceuticals. It comes as 20mg Tablet.
What is RIVAROX used for?
Rivaroxaban is used for Atrial fibrillation, Strokes, Deep venous thrombosis.
What is the generic name of RIVAROX?
The generic name of RIVAROX is Rivaroxaban.
Which brands of Rivaroxaban are available in Nepal?
6 brands of Rivaroxaban are listed in the NepalDoc catalog, from 2 makers — including RIVAROX 10mg Tablet, RIVAROX 15mg Tablet, XARELTO 10MG Tablet, XARELTO 15MG Tablet, XARELTO 20MG Tablet.
What are the side effects of Rivaroxaban?
The following clinically significant adverse reactions are also discussed in other sections of the labeling: Increased Risk of Stroke After Discontinuation in Nonvalvular Atrial Fibrillation Bleeding Risk Spinal/Epidural Hematoma The most common adverse reaction (>5%) in adult patients was bleeding The most common adverse reactions (>10%) in pediatric patients were bleeding, cough, vomiting, and gastroenteritis To report…
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
